Type of security: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
The data is delayed by 15 minutes.
AMGN is in the long-term up 396% in 17 years.
Description: Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Its principal products include Neulasta, a pegylated protein for the treatment of chemotherapy-induced febrile neutropenia; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for treating the patients with non-myeloid malignancies; and Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. The company?s principal products also comprise Aranesp and EPOGEN erythropoiesis-stimulating agents for the treatment of anemia and dialysis; XGEVA and Prolia for the prevention of skeletal-related events and treatment of postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Its other marketed products include Nplate
|Shares Outstanding||EPS||10.63||EPS Growth - 4 Quarters||-5.54%||EPS Growth - Q/Q||23.37%|
|EPS Growth - Y/Y||-9.79%||Sales Growth - 4 Quarters||-2.84%||Sales Growth - Q/Q||-5.59%||P/E||15.28|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||8.28%||ROE||21.53%||ROI||9.63%|
|Current Ratio||5.53||Quick Ratio||5.11||Long Term Debt/Equity||1.04||Debt Ratio||0.24|
|Gross Margin||78.78%||Operating Margin||33.29%||Net Profit Margin||27.74%||Dividend Payout Ratio||-34.86%|
|Cash From Financing Activities||-1.24 B||Cash From Investing Activities||-952 M||Cash From Operating Activities||1.33 B||Gross Profit||4.57 B|
|Net Profit||1.65 B||Operating Profit||2.08 B||Total Assets||71.21 B||Total Current Assets||37.74 B|
|Total Current Liabilities||6.89 B||Total Debt||31.95 B||Total Liabilities||43.73 B||Total Revenue||5.37 B|
|High 52 week||206.65||Low 52 week||165||Last close||194.87||Last change||5.95%|
|RSI||76.37||Average true range||5.08||Beta||0.85||Volume||2.05 M|
|Simple moving average 20 days||8.76%||Simple moving average 50 days||8.94%||Simple moving average 200 days||5.51%|
|Performance Week||4.82%||Performance Month||10.25%||Performance Quart||15.18%||Performance Half||5.58%|
|Performance Year||0.68%||Performance Year-to-date||0.88%||Volatility daily||2%||Volatility weekly||4.47%|
|Volatility monthly||9.16%||Volatility yearly||31.75%||Relative Volume||183.77%||Average Volume||2.88 M|
|New High||New Low|
2020-06-02 06:00:00 | Here Are Six Dividend Stocks With Solid Payout Prospects—and a Built-In Exit Strategy
2020-06-01 08:00:00 | Biotech ETFs Are Soaring. These Four Are Still Worth Considering.
2020-06-01 07:47:11 | Drugmakers Focus on Coronavirus Vaccine by 2020: 4 Winners
2020-05-30 11:31:03 | Why Is Amgen AMGN Down 4% Since Last Earnings Report?
2020-05-29 19:38:00 | Betting on Boeing to Fly Out of the Storm Clouds
2020-05-29 12:39:04 | Top Stock Reports for Novo Nordisk, IBM & Honeywell
2020-05-28 17:00:00 | Amgen To Present At The Jefferies 2020 Virtual Healthcare Conference
2020-05-28 16:13:51 | Why This Event Could Clear The Deck For An Alexion Takeover: Analyst
2020-05-28 14:16:00 | Nasdaq Today: Why Alexion and Workday Stock Are Soaring
2020-05-28 09:27:00 | Alexion Stock Jumps on Signal That Fight Over Patent May End Soon
2020-05-27 15:03:58 | Hedge Funds Started Cashing Out Of Amgen, Inc. AMGN
2020-05-27 13:16:22 | As Amgen Stock Trades Near Key Support, Consider This Bullish Option Trade
2020-05-27 10:00:53 | Is Amgen Stock A Buy As It Takes A Two-Pronged Approach To Coronavirus?
2020-05-26 07:52:11 | Coronavirus Vaccine Development Gathers Steam: 4 Winners
2020-05-20 19:00:00 | Amgen Announces Voting Results Of Annual Meeting Of Stockholders
2020-05-19 08:03:12 | 5 Biotech Stocks in Focus as Race for Coronavirus Vaccine Heats Up
2020-05-19 08:00:53 | Biotech Giant Amgen Is Nearing A Breakout, But Is AMGN Stock A Buy?
2020-05-18 15:37:10 | We could still see a V-Shaped recovery: Expert
2020-05-18 12:00:04 | Amgen AMGN Upgraded to Buy: What Does It Mean for the Stock?
2020-05-14 10:46:00 | Merck, Roche, Amgen Stocks React to Release of Cancer-Drug Data
2020-05-13 15:45:05 | Dow Jones Slides 1,171 Points In 3 Days After Fed Chair Speech Sharpens Recession Fear
2020-05-13 14:35:00 | Earnings season shows how fast companies have upped their digital game, says Goldman
2020-05-13 06:32:00 | Is Now Still a Good Time To Buy Amgen?
2020-05-12 13:36:05 | The Zacks Analyst Blog Highlights: Amgen, BHP, Altria, Apple and Target
2020-05-11 13:23:05 | Top Research Reports for Amgen, BHP, Altria & Others
2020-05-11 09:07:00 | Why Amgen Soared in April
2020-05-10 08:04:35 | Should You Buy Amgen Inc. NASDAQ:AMGN For Its Upcoming Dividend In 4 Days?
2020-05-08 16:24:08 | Are Biotech ETFs in Trouble as Coronavirus Dims Guidance?
2020-05-08 11:23:17 | 5 Biopharmas Where BofA Would Put Its Money To Work
2020-05-08 08:30:10 | FDA Grants Fast Track Designation for Omecamtiv Mecarbil in Heart Failure
2020-05-07 11:24:25 | Akebia Shares Climb on Positive Anemia Drug Study Results
2020-05-06 08:19:00 | Adaptive, Microsoft to conduct study evaluating T-cells in COVID-19 patients
2020-05-05 15:26:42 | Coronavirus U.S. death toll may hit 134k+ by early August, study reveals
2020-05-05 11:50:00 | Why Akebia Therapeutics Stock Is Crushing It Today
2020-05-05 09:00:00 | KYPROLIS® carfilzomib Patents Upheld Against Generic Manufacturer
2020-05-05 07:21:00 | Akebia's shares jump on late-stage clinical trial results for kidney disease drug
2020-05-04 17:59:35 | Cytokinetics Trading at Half High Target of $30
2020-05-04 15:12:59 | Trump expresses confidence for coronavirus vaccine ‘by the end of the year’
2020-05-01 22:44:48 | Edited Transcript of AMGN earnings conference call or presentation 30-Apr-20 9:30pm GMT
2020-05-01 10:54:02 | Amgen AMGN Q1 Earnings Top, to Study Otezla for Coronavirus
2020-05-01 08:00:53 | Biotech Amgen Is Tackling Coronavirus From Two Sides — But Is It A Buy?